Trefoil Peptides in Lung Diseases

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Bispebjerg Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT00839735
First received: February 6, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

The study focuses on trefoil family factor (TFF) peptides in sputum in lung diseases. The investigators hypothesize that TFF peptides are upregulated in lung diseases characterized by mucus hypersecretion.


Condition
Chronic Obstructive Pulmonary Disease
Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Trefoil Peptides in Lung Diseases

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • TFF in sputum [ Time Frame: Monthly ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: February 2009
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
COPD
Chronic obstructive pulmonary disease
Asthma
Healthy controls

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Subjects with chronic obstruction pulmonary disease (COPD) Subjects with asthma Healthy volunteers

Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Informed consent

Exclusion Criteria:

  • Upper and lower airway infection 2 weeks prior to visit 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00839735

Contacts
Contact: Thomas K Lund, MD PhD (+45) 35 31 30 69 tclund@dadlnet.dk
Contact: Lars Pedersen, MD PhD (+45) 35 31 30 69 lars.pedersen@dadlnet.dk

Locations
Denmark
Respiratory and Allergy Research Unit, Department of Respiratory Medicine L, Bispebjerg Hospital Recruiting
Copenhagen, Denmark, 2400
Contact: Thomas K Lund, MD PhD    (+45) 35 31 30 69    tclund@dadlnet.dk   
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
Principal Investigator: Thomas K Lund, MD PhD Respiratory and Allergy Research Unit
  More Information

No publications provided

Responsible Party: Thomas K. Lund (MD PhD) & Lars Pedersen (MD PhD), Respiratory and Allergy Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark
ClinicalTrials.gov Identifier: NCT00839735     History of Changes
Other Study ID Numbers: H-B-2008-120
Study First Received: February 6, 2009
Last Updated: February 6, 2009
Health Authority: Denmark: Ethics Committee
Denmark: Danish Dataprotection Agency

Keywords provided by Bispebjerg Hospital:
COPD

Additional relevant MeSH terms:
Asthma
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on July 26, 2014